Overall Survival After Concurrent Cisplatin–Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma
J. Natl. Cancer Inst. Chan et al.
97: 536
Supplementary Figures
The following supplementary figures accompany this Brief Communication:
Files in this Data Supplement:
- Supplementary Fig. 1. -
Progression-free survival by treatment arm for all patients.Patients treated with cisplatin and radiotherapy (RT) (solid lines). Patients treated with RT alone (broken lines). Numbers in italics represent numbers of patients at risk. Hazard ratio = 0.74 (95% CI = 0.54 to 1.0); P = .06 (two-sided), using Cox regression analysis after adjustment for tumor stage, age, and overall stage.
- Supplementary Fig. 2. -
Progression-free survival by treatment arm for patients with tumor stage 3 and 4. Patients treated with cisplatin and radiotherapy (RT) (solid lines). Patients treated with RT alone (broken lines). Numbers in italics represent numbers of patients at risk. Hazard ratio = 0.53 (95% CI = 0.33 to 0.88); P = .012 (two-sided), using Cox regression analysis.
- Supplementary Fig. 3. -
Patients free from local recurrence by treatment arm for patients with tumor stage 3 and 4. Patients treated with cisplatin and radiotherapy (RT) (solid lines). Patients treated with RT alone (broken lines). Numbers in italics represent numbers of patients at risk. Hazard ratio = 0.45 (95% CI = 0.21 to 1.0); P = .051 (two-sided), using Cox regression analysis.
- Supplementary Fig. 4. -
Patients free from distant metastasis by treatment arm for patients with tumor stages 3 and 4. Patients treated with cisplatin and radiotherapy (RT) (solid lines). Patients treated with RT alone (broken lines). Numbers in italics represent numbers of patients at risk. Hazard ratio = 0.65 (95% CI = 0.37 to 1.2); P = .15 (two-sided), using Cox regression analysis.
